on behalf of the SPARK-AML1 Investigators BACKGROUND: In this phase 2 study, the authors evaluated the efficacy, safety, and tolerability of the Aurora B kinase inhibitor barasertib compared with low-dose cytosine arabinoside (LDAC) in patients aged 60 years with acute myeloid leukemia (AML). METHODS: Patients were randomized 2:1 to receive either open-label barasertib 1200 mg (as a 7-day intravenous infusion) or LDAC 20 mg (subcutaneously twice daily for 10 days) in 28-day cycles. The primary endpoint was the objective complete response rate (OCRR) (complete responses [CR] plus confirmed CRs with incomplete recovery of neutrophils or platelets [CRi] according to Cheson criteria [also requiring reconfirmation of CRi 21 days after the first appearance and associated with partial recovery of platelets and neutrophils]). Secondary endpoints included overall survival (OS) and safety. RESULTS: In total, 74 patients (barasertib, n 5 48; LDAC, n 5 26) completed 1 cycle of treatment. A significant improvement in the OCRR was observed with barasertib (35.4% vs 11.5%; difference, 23.9%; 95% confidence interval, 2.7%-39.9%; P <.05). Although the study was not formally sized to compare OS data, the median OS with barasertib was 8.2 months versus 4.5 months with LDAC (hazard ratio, 0.88; 95% confidence interval, 0.49-1.58; P 5.663). Stomatitis and febrile neutropenia were the most common adverse events with barasertib versus LDAC (71% vs 15% and 67% vs 19%, respectively). CONCLUSIONS: Barasertib produced a significant improvement in the OCRR versus LDAC and had a more toxic but manageable safety profile, consistent with previous studies. Cancer 2013;000:000-000. V C 2013 American Cancer Society.
INTRODUCTION
Acute myeloid leukemia (AML) presents more frequently with advancing age. 1, 2 With standard intensive induction chemotherapy, 5-year survival rates in patients aged <60 years approach 50%; however, in older patients, prognosis remains poor. 3, 4 In a recent study of 446 patients aged >70 years who received intensive cytarabine chemotherapy between 1990 and 2008, the median survival did not exceed 6 months, and mortality rates 30% were noted at 8 weeks. 5 Patient-related and drug-related factors, including age, contraindications/reduced tolerability to chemotherapy, and a poor cytogenetic risk profile, account for poor survival outcomes in elderly patients with AML. 3, 5 To date, low-dose cytosine arabinoside (LDAC) is the only agent that has demonstrated clinical benefit in randomized studies of patients aged 60 years with AML who are not considered fit to receive intensive induction chemotherapy, 6 and improvement in survival rates among elderly patients remains an elusive treatment goal. 7 Aurora kinases are a family of proteins (Aurora A, Aurora B, and Aurora C) that are known to play an integral role in the regulation of mitosis and chromosomal segregation. 8, 9 Observed over-expression in a variety of cancers, including AML, together with evidence of a potential for oncogenic transformation with increased activity, [10] [11] [12] [13] [14] [15] implicate Aurora B kinase as a rational target for small-molecule anticancer therapy. Barasertib is a prodrug that rapidly undergoes phosphatase-mediated cleavage in serum to release barasertib-hQPA, a highly potent and selective inhibitor of Aurora B kinase.
Preclinical evidence of efficacy with barasertib (growth inhibition and survival in AML models) [16] [17] [18] [19] also extends to the clinical setting, in which preliminary anti-AML activity has been demonstrated in early phase clinical studies. [20] [21] [22] [23] The current study was designed with 2 stages. Here, we report findings from stage I, in which we compare the efficacy, safety, and tolerability of barasertib and LDAC in elderly patients with newly diagnosed AML. The results would then inform the decision to proceed to stage II, to determine the relative efficacy of barasertib alone and in combination with LDAC compared with LDAC alone.
MATERIALS AND METHODS

Patients
Eligible patients were aged 60 years with newly diagnosed de novo or secondary AML (excluding acute promyelocytic leukemia and blast crisis of chronic myeloid leukemia) who were considered unsuitable for intensive induction with anthracycline-based chemotherapy and who had a World Health Organization performance status from 0 to 3 (a performance status of 3 was acceptable if it was solely attributable to the underlying leukemia). Patients also had to be considered likely to complete 3 cycles of treatment. Unsuitability for intensive chemotherapy was determined by the treating physician in discussion with the patient and also required at least 1 of the following: age 75 years, adverse cytogenetics, a World Health Organization performance status >2, and organ dysfunction arising from significant comorbidities not directly related to leukemia. Exclusion criteria included serum bilirubin >1.5 times the upper limit of normal (ULN); aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >2.5 times the ULN; serum creatinine >1.5 times the ULN or 24-hour creatinine clearance 50 mL per minute (according to Cockcroft-Gault criteria); central nervous system disease because of leukemic infiltration; selected, uncontrolled, intercurrent illness; QTc 470 msec; administration of anticancer agents within the 2 weeks before the start of study treatment; and clinically significant toxicity (National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] grade >1) related to treatment with anticancer agents. All patients provided written informed consent. Administration of hydroxyurea before and up to 3 days into cycle 1 was allowed at the discretion of the investigator. This was limited to patients who had a white blood count 25 3 10 9 /L, and the total duration of hydroxyurea could not exceed 7 days.
Study Design
This was an open-label, randomized, 2-stage, phase 2 study of barasertib versus LDAC (ClinicalTrials.gov identifier NCT00952588) conducted at 46 centers across Australia, Europe, Japan, and the United States. Patients were randomized 2:1 to receive either open-label barasertib (1200 mg as a 7-day continuous intravenous infusion from day 1 to day 8) or LDAC (20 mg as a subcutaneous injection twice daily for 10 days) in 28-day cycles. Unless considered inappropriate by the investigator, patients were expected to complete at least 3 cycles (12 weeks) of treatment. Additional cycles could be administered at the discretion of the investigator if the patient was considered to be deriving clinical benefit. The trial was approved by the relevant institutional ethical committees or review bodies and was conducted in accordance with the Declaration of Helsinki, the International Conference on Harmonization/Good Clinical Practice, and the AstraZeneca policy on bioethics. 24 The primary endpoint for stage I of this study was the objective complete response rate (OCRR), defined as the proportion of patients achieving a complete response (CR) and a confirmed CR with incomplete recovery of neutrophils or platelets (confirmed CRi; measured according to criteria established by the International Working Group for AML trials, 25 but also requiring partial recovery of neutrophils and platelets in the absence of transfusions and with confirmation of the CRi 21 days after the first appearance). Secondary endpoints included the duration of response, the time to response, overall survival (OS), disease-free survival (DFS) in responders, and safety.
Assessments
Blood samples and bone marrow aspirates were collected at baseline and at the end of each cycle; if an aspirate could not be obtained, then an optional trephine biopsy was requested. Bone marrow aspirates/biopsies and peripheral blood samples were assessed by blinded independent central review. Patients who achieved a CR or a confirmed CRi were followed every 4 weeks to assess the duration of response.
Safety assessments were conducted throughout the study and comprised the incidence of adverse events (AEs), graded according to NCI CTCAE version 3.0, and changes in vital signs, clinical laboratory parameters, and electrocardiograms.
Statistical Analysis
The sample size for stage I was based on the assumption that, with 75 patients, there was 80% probability of observing at least a 10% difference in the OCRR, assuming that the true LDAC and barasertib OCRR rates were 18% 6 and 36%, respectively. Efficacy analyses in stage I were performed on the modified intention-to-treat set, which included all randomized patients who commenced study treatment. Treatment differences (and 95% confidence intervals) for the primary endpoint of OCRR were calculated according to the Newcombe-Wilson method. 26 Estimates of OS were obtained using log-rank testing and Kaplan-Meier analysis. Additional response and OS analyses were conducted in patients grouped according to previously established profiles of cytogenetic risk. 27 Safety data were summarized descriptively.
RESULTS
Patients
Between August 2009 and July 2010, 77 patients (median age, 76 years; range, 61-85 years) were randomized to receive either barasertib (n 5 51) or LDAC (n 5 26). Three patients who were randomized to the barasertib arm did not receive study treatment because they died (n 5 1) or because they no longer met the eligibility criteria (n 5 2). Baseline demographic and clinical characteristics were generally comparable between the treatment groups (Table 1) . However, differences between the barasertib and LDAC arms were observed for the proportion of patients within the age category 75 years (65% vs 27%, respectively), those with "unknown" cytogenetics (by central analysis; 29% vs 15%, respectively), and those with a World Health Organization performance status of 3 (6% vs 15%, respectively).
Efficacy
Treatment with barasertib was associated with a significant improvement in OCRR compared with LDAC treatment (35% [n 5 17 of 48 patients] vs 12% [n 5 3 of 26 patients]), which equated to a difference of 24% in favor of barasertib (95% confidence interval, 2.7-39.9; P < .05) ( Table 2 ). Response to barasertib treatment was reported across all cytogenetic risk groups, including an OCRR of 33% for the 9 patients who had adverse cytogenetics (Table 2) . By comparison, response to LDAC was confined to patients who had either favorable or intermediate cytogenetic risk. Differences identified in baseline demographic and clinical characteristics between treatment arms had a negligible impact on efficacy (data not shown).
Response to barasertib treatment was sustained for a median duration of 82 days (range, 28-321 days). The median duration of response to LDAC (3 responses) could not be determined but ranged between 30 days and 85 days. Most responses were achieved within 2 treatment cycles (barasertib, 12 of 17 responses; LDAC, 2 of 3 responses), corresponding to a median time to response of 59 days (range, 27-180 days) and 64 days (range, 63-96 days), respectively. Two patients who were randomized to receive barasertib, both with adverse cytogenetics, were ongoing in response at the time of data cutoff (Fig. 1) .
The median follow-up for patients who were alive at the time of data cutoff was 12.9 months in the barasertib group and 13.6 months in the LDAC group. Across both treatment arms, the minimum follow-up for patients who remained alive at the time of data cutoff was 11.2 months. There were 34 deaths (71%) in the barasertib group compared with 18 deaths (69%) in the LDAC group. Although stage I of the study was not formally sized to compare OS data, the median survival was 8.2 months for the barasertib group and 4.5 months for the LDAC group. This difference was not statistically significant (hazard ratio, 0.88; 95% confidence interval, 0.49-1.58; P 5 .663) (Fig. 2A) . The OS treatment effect was broadly similar within each of the cytogenetic risk groups, although the small numbers of patients in each subgroup precluded any definitive conclusions (Fig. 2B) .
Additional exploration of the OS results revealed that the proportion of patients who received subsequent anticancer therapy after progression was comparable between treatment groups (barasertib, n 5 11 [23%]; LDAC, n 5 7 [27%]). However, these therapies were classified as intensive in a greater proportion of LDACtreated patients (barasertib, n 5 4 [8%]; LDAC, n 5 7 [27%]). Moreover, the 3 patients who had the longest survival duration in the LDAC group had subsequently begun intensive anticancer therapy within 3 months of randomization. In both groups, pyrimidine analogs were the most commonly administered subsequent anticancer therapies.
The median DFS among barasertib-treated patients who achieved a CR or a CRi was 5.6 months (range, 2.0-12.5 months). The median DFS with LDAC (based on 3 responses) could not be determined but ranged between 2.3 months and 5.9 months.
Safety
All patients who commenced therapy within this study received at least 1 cycle of treatment (Fig. 3) . Of the completed cycles, most patients received 80% of the planned dose (barasertib, n 5 45 [94% of the planned dose]; LDAC, n 5 24 [92% of the planned dose]).
The AEs (any grade; any cause) that occurred most commonly and with higher incidence in the barasertib group versus the LDAC group were stomatitis (71% vs 15%), febrile neutropenia (67% vs 19%), and diarrhea (50% vs 12%) ( Table 3 ). The overall incidence of grade 3 AEs was higher in the barasertib group (n 5 40; 83%) compared with the LDAC group (n 5 18; 69%), with grade 3 febrile neutropenia (50% vs 19%), stomatitis/ mucositis (29% vs 0%), and pneumonia (23% vs 8%) reported more frequently (15% higher incidence) in the barasertib group than in the LDAC group (Table 3) . Grade 3 infection events (grouped) also occurred at a higher incidence (>15%) in the barasertib group compared with the LDAC group (40% vs 23%, respectively), with pneumonia and lobar pneumonia the most commonly reported infection event in either treatment group (barasertib, 25%; LDAC, 8%).
Serious AEs (SAEs) were reported in 23 (48%) barasertib-treated patients and in 10 (39%) LDAC-treated patients. In the barasertib group, SAEs observed in >1 patient were pneumonia (including lobar pneumonia; n 5 6; 13%), febrile neutropenia (n 5 5; 10%), pyrexia (n 5 4; 8%), stomatitis (n 5 3; 6%), and neutropenia (n 5 2; 4%). For the LDAC group, the only SAE reported in >1 patient was pneumonia (n 5 2; 8%). AEs led to dosing modifications in 5 patients overall (barasertib, n 5 3; LDAC, n 5 2). In 2 patients (both in the barasertib group), stomatitis (n 5 1) and stomatitis plus febrile neutropenia (n 5 1) resolved with a reduction in dose. Interruption of dosing because of AEs was noted for 1 patient in the barasertib arm (grade 2 extravasation) and for 2 patients in the LDAC arm (n 5 1, chills and hypoxia events; n 5 1, pharyngitis); effective resolution of the event was reported for the barasertib-treated patient only.
Four patients (8.3%) discontinued barasertib treatment because of AEs of infective arthritis, febrile neutropenia, neutropenia, and renal failure; 2 patients (7.7%) in the LDAC arm discontinued because of pneumonia. The events of febrile neutropenia, neutropenia, and renal failure were considered by the investigator to be related to treatment.
Deaths that occurred as a consequence of AEs were reported for 6 patients (13%) in the barasertib arm (pneumonia and lobar pneumonia [previously reported as SAEs], n 5 4; pulmonary mycosis, n 5 1; acute renal failure, n 5 1) and for 3 patients (12%) in the LDAC arm (pneumonia and lobar pneumonia [previously reported as a SAE]; Clostridium difficile sepsis; sepsis; all n 5 1); none of these events were judged treatment related, with the exception of sepsis, which was deemed to be related to LDAC treatment. Furthermore, mortality rates for each treatment group were evaluated at 30-day intervals (Table 4) . At 30 days from the start of treatment, mortality rates were similar between treatment groups; whereas, at 60 days and 90 days, the rates were numerically lower in the barasertib group. There were no clinically significant changes in clinical laboratory parameters pertaining to liver or renal function or in vital signs after treatment with either barasertib or LDAC. 
DISCUSSION
To our knowledge, this is the first study to investigate barasertib versus a standard of care in AML. The first stage of this open-label, randomized study met its primary endpoint, demonstrating a significant and apparently durable improvement in OCRR with barasertib compared with LDAC in patients aged >60 years with newly diagnosed AML who were considered unfit for intensive chemotherapy. The magnitude of response observed in this study was up to 2-fold higher than that observed with preliminary signals in previously reported barasertib monotherapy studies, 22, 23 but it was similar to that reported in a previous phase 1 dose-escalation study of barasertib in combination with LDAC. 21 Furthermore, barasertib treatment demonstrated responses across all cytogenetic risk groups; a potential benefit was indicated for those patients with adverse cytogenetic profiles, although the patient numbers were too small to make any definitive conclusions.
Survival analysis revealed a numerical trend in favor of barasertib in this population of elderly patients with AML. The failure to observe a more distinct result between treatment groups may reflect the lack of power in this study to detect a robust treatment effect on survival. However, previous studies with LDAC suggest that more death events may have been expected 11 months postrandomization than were observed in this study. 6, 28 On further analysis, an imbalance in subsequent intensive therapy received postdiscontinuation of randomized treatment (8% in the barasertib group compared with 27% in the LDAC group) also may have influenced these OS findings, although the small sample numbers preclude any robust conclusions. Safety results were consistent with the known tolerability profile of barasertib in monotherapy studies. 20, 22, 23 Febrile neutropenia and stomatitis/mucositis, as expected, occurred at a higher incidence in patients who received barasertib compared with those who received LDAC. Overall, observed AEs generally resolved and led to a dose modification in only a small proportion of patients. Despite the increased tolerability burden from barasertib treatment, cumulative toxicities were not observed with barasertib treatment, and rates of drug discontinuation and mortality were similar for the barasertib group and the LDAC group. Although it was expected that patients enrolled in this study were to receive a minimum of 3 treatment cycles, in reality, only approximately 50% of patients received >1 cycle. The reasons for discontinuation after only 1 or 2 cycles were investigated and were considered justified, eg rising blast counts or no response. Early mortality rates with barasertib treatment observed here were superior to findings from a previous study of older patients with AML who received intensive chemotherapy, which reported 8-week mortality rates in excess of 30%. 5 Recent studies of other agents with activity versus Aurora kinases have also demonstrated preliminary evidence of anticancer activity. These include AMG900, 29 a pan-Aurora kinase inhibitor currently being investigated in a phase 1 trial in adult patients with acute leukemias (NCT01380756). However, because AMG900 is not selective for Aurora B, it remains to be established whether the antileukemia activity observed with this agent is because of an effect on Aurora B and/or other target(s). The Aurora A kinase inhibitor MLN8237 has demonstrated preclinical anti-AML activity 30 and is currently in a phase 2 trial in patients with AML or myelodysplastic syndrome (NCT00830518).
The significant favorable response to barasertib treatment versus LDAC observed in this study confirms and extends preliminary signals of efficacy observed in older patients with AML. On the basis of these results, AstraZeneca is considering further development options for this active compound in this area of high unmet medical need.
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